StreetAlpha.app
Home › Stocks › CRMD

CorMedix Inc. (CRMD)

Healthcare
$5.27
▲ +3.74%
LAST CLOSE · NOV 20

CorMedix develops and sells DefenCath, a catheter lock solution for dialysis patients, plus hospital infection drugs and a heart medicine. It last closed at $5.27 on Nov 20, up 3.74% on the day. The next earnings report for CRMD is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, CRMD reported EPS of -$0.19 on revenue of $54.5M, with revenue down 47.7% from a year ago. Over its last 8 reports the stock moved an average of 15.3% the session after earnings. Over the last 12 months CRMD insiders bought $588K of stock on the open market and sold $2.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is CRMD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CRMD.

Key Stats

Last 12 months
Results
Revenue
$412.5M
+92.5% vs a year ago
Net income
$63.9M
−60.7% vs a year ago
EPS (diluted)
$0.64
−71.0% vs a year ago
Free cash flow
$307.9M
74.6% margin
Valuation
Market cap
$419.2M
79.5M shares
P/E
8.2
Price over 12 month EPS
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$355.1M
At Sep 30
Shareholder equity
$461.7M
Shares outstanding
79.5M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $191K$191KFY2021FY2022: $65K$65KFY2022FY2024: $43.5M$43.5MFY2024FY2025: $311.7M$311.7MFY2025

From CRMD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.19
Quarter ended Sep 2026
Year ago EPS
$1.26
−115.1% on a GAAP basis
Revenue
$54.5M
−47.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.24Dec '24Mar 2025: $0.30Mar '25Jun 2025: $0.28Jun '25Sep 2025: $1.26Sep '25Dec 2025: $0.07Dec '25Mar 2026: $0.43Mar '26Jun 2026: $0.29Jun '26Sep 2026: -$0.19Sep '26Latest -$0.19
Revenue by quarter
Dec 2024: $31.2MDec '24Mar 2025: $39.1MMar '25Jun 2025: $39.7MJun '25Sep 2025: $104.3MSep '25Dec 2025: $128.6MDec '25Mar 2026: $127.4MMar '26Jun 2026: $101.9MJun '26Sep 2026: $54.5MSep '26Latest $54.5M
How CRMD moved after its last 8 reports
Average move the session after a report ±15.3%
Nov 2, 2026Time not announced−5.4%
Aug 13, 2026Time not announced+14.7%
May 14, 2026Time not announced+5.7%
Mar 5, 2026Time not announced−11.5%
Jan 8, 2026Time not announced−32.8%
Oct 20, 2025Time not announced+19.4%
Aug 7, 2025Time not announced−9.5%
May 6, 2025Time not announced+23.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CRMDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CRMD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CRMD

Technical Analysis

CRMD · as of the Nov 20 close · updated each morning
Downtrend

The stock is 9% below its 20 day and 30% below its 50 day average. It is 42% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot at $5.18, and the nearest resistance the Pivot R1 at $5.41.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.9%/day
Key levels
$13.0252 week high+147.1%
$7.66Swing high (Aug 4)+45.4%
$7.49200 day average+42.1%
$7.46100 day average+41.6%
$6.8650 day average+30.2%
$5.7320 day average+8.7%
$5.41Pivot R1+2.7%
$5.27Last close
$5.18Pivot−1.7%
$5.10Swing low (Nov 6)−3.2%
$5.04Pivot S1−4.4%
$4.4652 week low−15.4%
Indicators
RSI (14)40.39Middle of its rangeNeutral
MACD-0.65Above its signal lineBullish
Stochastic35.9Middle of its rangeNeutral
ADX (14)34.4Trending down
Williams %R-39.3Oversold below −80, overbought above −20Neutral
CCI (20)-44.1Oversold below −100, overbought above 100Neutral
Rate of change−0.9%Change over 10 sessionsBearish
ATR (14)$0.42Typical daily range, 7.9% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRMD

What happened before

See how CRMD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CRMD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CRMD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CRMDHow many large options trades hit CRMD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

CRMD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●89 buying vs 87 selling
  • ▲Held by funds +6.7 pts
  • ▼Funds holding -6
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding189195−3.1%
In funds' top 1000–
Held by funds62.0%55.3%+6.7 pts
New / increased21 / 6827 / 67−5.3%
Reduced / sold out61 / 2659 / 21+8.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRMD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CRMD Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$588K4 buys · 4 insiders
Sold$2.3M7 sales · 4 insiders
68% of the selling was under pre-arranged trading plans.
Cluster buy: 4 insiders bought $588K between Nov 13 and Nov 19.
2025-12 sold $2.0M2026-01 sold $69K2026-11 bought $588KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19Susan BlumCFOBuy5,000$4.58$23K
Nov 18Steven W LefkowitzDirectorBuy11,500$4.53$52K
Nov 16Myron KaplanDirectorBuy25,000$4.88$122K
Nov 13Joseph TodiscoCEOBuy80,000$4.89$391K
Jan 21Janet DillioneDirectorSale plan10,000$6.88$69K
Dec 30, 2025Alan W DuntonDirectorSale plan20,000$13.00$260K
Every insider buy and sale for CRMD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CRMD insider trades →

From SEC Form 4 filings by CRMD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRMD is in one of them and how their past CRMD trades turned out.

CRMD in the AI portfolios
Loading…

CRMD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRMD in an article yet. Here's the latest on the wider market.

CRMD in the news

About CorMedix

CorMedix is a biopharmaceutical company based in Parsippany, New Jersey, that develops and sells drugs for serious medical conditions. Its main product is DefenCath, a catheter lock solution that helps reduce bloodstream infections in adult kidney failure patients who receive dialysis through a central venous catheter. Its customers are mainly outpatient dialysis clinics and hospitals. The company also sells a set of hospital-focused drugs for serious infections, including REZZAYO and VABOMERE, along with the heart drug TOPROL XL. These products are used in hospitals, emergency departments, outpatient clinics and home infusion care.

Headquarters
Parsippany, NJ